BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Total Current Assets
All assets expected to be converted to cash or used up within one year.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 88.6% from a year ago
Total current assets stood at $266.5M at the end of Q1 FY2026, up 88.6% from a year earlier and down 37.4% from the prior quarter.
Context
- Total current assets amounted to 63.8% of total assets at the end of Q1 FY2026, down 30.5 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +88.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 425.46M USD
- Year-over-year change
- +21721.0%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 425.46M | +21721.0% |
| FY2024 | 2024-12-31 | 1.95M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Current Assets vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +88.6% is the 3rd highest of 10, against a peer median of +4.4%.
- Total current assets amounts to 63.8% of total assets for BBOT, versus a peer median of 92.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Aug 2026 | $1.1B USD | +150.5% | +24.0% | 92.3% | |
| Sep 2026 | $992.67M USD | +506.1% | -1.9% | 96.1% | |
| Jun 2026 | $523.21M USD | +2.0% | -3.9% | 72.2% | |
SEPNSepterna, Inc. | Sep 2026 | $507.35M USD | +3.2% | +134.4% | 81.9% |
| Mar 2026 | $316.11M USD | -12.9% | -7.8% | 95.9% | |
| Mar 2026 | $276.57M USD | +4.4% | +12.6% | 90.6% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $266.5M USD | +88.6% | — | 63.8% |
| Mar 2026 | $237.46M USD | +0.1% | +13.0% | 93.6% | |
| Mar 2026 | CHF 226.36M CHF | +19.9% | +110.0% | 93.1% | |
| Sep 2026 | $92.89M USD | +22.7% | -23.8% | 44.4% | |
| Peer median (excluding BBOT) | — | +4.4% | +12.6% | 92.3% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.